88 related articles for article (PubMed ID: 30132569)
1. Clinical relevance of the multidrug resistance‑associated protein 1 gene in non‑small cell lung cancer: A systematic review and meta‑analysis.
Hu P; Wong PT; Zhou Q; Sheng L; Niu W; Chen S; Xu M; Lin Y
Oncol Rep; 2018 Nov; 40(5):3078-3091. PubMed ID: 30132569
[TBL] [Abstract][Full Text] [Related]
2. Integrin-Linked Kinase, Snail and Multidrug Resistance Protein 1: Three concordant players in the progression of non-small cell lung cancer.
Abd El-Rehim DM; Abd-Elghany MI; Nazmy MH
J Egypt Natl Canc Inst; 2015 Sep; 27(3):129-37. PubMed ID: 25964055
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.
Berger W; Setinek U; Hollaus P; Zidek T; Steiner E; Elbling L; Cantonati H; Attems J; Gsur A; Micksche M
J Cancer Res Clin Oncol; 2005 Jun; 131(6):355-63. PubMed ID: 15856298
[TBL] [Abstract][Full Text] [Related]
4. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.
Li J; Li ZN; Du YJ; Li XQ; Bao QL; Chen P
Clin Lung Cancer; 2009 Nov; 10(6):414-21. PubMed ID: 19900859
[TBL] [Abstract][Full Text] [Related]
5. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy.
Li J; Li ZN; Yu LC; Bao QL; Wu JR; Shi SB; Li XQ
Lung Cancer; 2010 Jul; 69(1):116-22. PubMed ID: 19875192
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and prognostic value of S100A4 expression in non-small cell lung cancer: a meta-analysis.
Zhang J; Gu Y; Liu X; Rao X; Huang G; Ouyang Y
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32696952
[TBL] [Abstract][Full Text] [Related]
7. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and prognostic significance of NM23 expression in patients with non-small cell lung cancer: A systematic review and meta-analysis.
Min SH; Zheng QQ
Medicine (Baltimore); 2021 Nov; 100(47):e27919. PubMed ID: 34964763
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.
Chen YL; Yang TY; Chen KC; Wu CL; Hsu SL; Hsueh CM
Cell Oncol (Dordr); 2016 Oct; 39(5):411-433. PubMed ID: 27306525
[TBL] [Abstract][Full Text] [Related]
10. The expression of hypoxia-inducible factor-1α and its clinical significance in lung cancer: a systematic review and meta-analysis.
Ren W; Mi D; Yang K; Cao N; Tian J; Li Z; Ma B
Swiss Med Wkly; 2013; 143():w13855. PubMed ID: 24018850
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
12. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
13. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC).
Doubre H; Césari D; Mairovitz A; Bénac C; Chantot-Bastaraud S; Dagnon K; Antoine M; Danel C; Bernaudin JF; Fleury-Feith J
Int J Cancer; 2005 Feb; 113(4):568-74. PubMed ID: 15472893
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis.
Xuan ZX; Zhang S; Yuan SJ; Wang W; Yu J
World J Surg Oncol; 2016 Sep; 14(1):237. PubMed ID: 27589869
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
17. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
Cicenas S; Zaliene A; Atkocius V
Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.
Yang SL; Ren QG; Wen L; Hu JL
J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):321-327. PubMed ID: 27376798
[TBL] [Abstract][Full Text] [Related]
19. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
20. MRP1 and GSTp1 expression in non-small cell lung cancer does not correlate with clinicopathological parameters: A Slovakian population study.
Rybárová S; Hodorová I; Mihalik J; Mirossay L
Acta Histochem; 2014 Oct; 116(8):1390-8. PubMed ID: 25258012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
